TMZ

IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
月曜日, 6月 3, 2024
GBM, ASCO, TMZ, MGMT, Glioblastoma, Patient, Cell, Annual general meeting, Glioma, Neuro, Safety, Society, IDH, Cohort, DRI, Stupp, Clinical trial, PFS, Cytokine release syndrome, Platelet, Neoplasm, Survival, University, Progression-free survival

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies, presented encouraging preliminary clinical data of INB-200 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 1, 2024.

Key Points: 
  • The Phase 1 study assessed the safety and preliminary efficacy of the addition of DeltEx DRI gamma-delta T cells to maintenance therapy with TMZ.
  • No treatment-related serious adverse events, dose-limiting toxicities, cytokine release syndrome, infusion reactions, or immune effector cell-associated neurotoxicity syndrome have been reported in any cohort.
  • The most common treatment emergent adverse events were Grade 1-2 toxicities consisting of white blood cell and platelet count decreases related to standard-of-care TMZ.
  • One subject was found to have a 36% decrease in a lesion attributed to positive treatment effect.

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

Retrieved on: 
月曜日, 6月 3, 2024
PD-1, GBM, ASCO, TMZ, Tokyo Stock Exchange, Brigham and Women's Hospital, Harvard Medical School, PD-L1, CD74, Patient, Trial of the century, Safety, Immunotherapy, Society, Hospital, Research, Dana–Farber Cancer Institute, Immunohistochemistry, Neuro-Oncology (journal), Clinical trial, PFS, Courage, Abstract, Macrophage, Neoplasm, Code, BID, Survival, Biopsy, Progression-free survival, CD3, Integrin alpha M

The primary endpoints were safety and tolerability of MN-166 and TMZ combination treatment and the efficacy of combination treatment.

Key Points: 
  • The primary endpoints were safety and tolerability of MN-166 and TMZ combination treatment and the efficacy of combination treatment.
  • No unexpected adverse effects were observed in both new GBM and recurrent GBM patients.
  • For the PFS6 primary efficacy endpoint, recurrent GBM patients showed a higher PFS6 rate compared to most historical studies.
  • We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial.”

IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Weakness, GBM, Patient, Progression-free survival, Headache, Drug, Urinary tract infection, Thrombosis, NK, PFS, EDT, TMZ, DRI, Balance disorder, Platelet, Cytokine release syndrome, KPS, Glioblastoma, NKG2D, Appetite, Neurotoxicity, Hydrocephalus, ASCO, Performance status, Fatigue, OS, Society, Annual general meeting, Medical imaging

INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistant gamma-delta T cells as a potential first-line treatment for patients with newly diagnosed glioblastoma multiforme (GBM).

Key Points: 
  • INB-200 is evaluating autologous Drug Resistant Immunotherapy (DeltEx DRI) or chemotherapy resistant gamma-delta T cells as a potential first-line treatment for patients with newly diagnosed glioblastoma multiforme (GBM).
  • “The current standard-of-care for newly diagnosed GBM has not advanced progression-free survival (PFS) beyond 4-7 months or overall survival beyond 14-16 months for over two decades,” said William Ho, CEO and co-founder, IN8bio.
  • “We’re excited to update the status of patients who received INB-200 for front-line GBM in addition to standard-of-care at the upcoming ASCO Annual Meeting.
  • Autologous DeltEx DRI is a gene-modified autologous gamma-delta T cell therapy designed for the treatment of newly diagnosed GBM patients receiving maintenance TMZ therapy.

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

Retrieved on: 
火曜日, 4月 30, 2024
University of Southern California, Efficacy, University, UCSD, Radiation, Resection, Regenerative medicine, HGG, TMZ, Doctor of Philosophy, RRV, GBM, WGS, Glioblastoma, Artificial intelligence, Depression, CIRM, UCSF, USC, Intravenous therapy, Neoplasm, Clinical trial, Medicine, SHROOM3, Whole genome sequencing, SAN, Medical imaging

We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.

Key Points: 
  • We are thrilled to continue the clinical development of our biomarker-guided DB107 gene therapy in HGG including GBM.
  • DB107 consists of two components: DB107–RRV (vocimagene amiretrorepvec) as a prodrug activator gene therapy and DB107–FC (extended-release 5–fluorocytosine [5–FC]) as an oral prodrug.
  • Retrospective analysis of an earlier randomized clinical trial in patients with recurrent HGG suggested improved overall survival in DGM7–positive patients treated with DB107.
  • "We are excited to conduct this novel trial which will be investigating several new approaches for the first time in patients with newly–diagnosed high–grade glioma.

Where’s Kate? Speculation about the ‘missing’ princess is proof the Palace’s media playbook needs a re-write

Retrieved on: 
水曜日, 3月 13, 2024
Online, Sandringham, Associated Press, Social media, Reuters, AFP, Breeding, Catherine, Princess of Wales, Easter, Coma, News, Incest, English, Duke, Pleasure, TMZ, Nausea, Vomiting, Pregnancy, Hysterectomy, Getty Images, Health, Princess, Hyperemesis gravidarum, Kensington Palace, Death, Practice, Divorce, Child, Comment, Buckingham Palace, Cancer

Social media have been awash with speculation about Catherine’s health and whereabouts.

Key Points: 
  • Social media have been awash with speculation about Catherine’s health and whereabouts.
  • As scrutiny reaches a fever pitch, we ask: why is the Palace’s typical media playbook no longer working?

Not so ‘unprecedented’

  • Anne Boleyn (circa 1501-1536), the second of six wives of Henry VIII, was executed after being found guilty of adultery, incest and treason.
  • The long-reigning Queen Victoria (1819-1901) was widely regarded as as a loyal wife and mother.
  • Yet she too became the target of gossip regarding her close friendship with Scottish servant John Brown after her husband, Prince Albert, died in 1861.

The Palace’s strategic communications

  • The royal family has gradually adjusted to new media and technologies, though not as quickly as the public might like.
  • On one hand, the Palace continues its age-old tradition of announcing major news on a noticeboard at the gates of Buckingham Palace.

Internet sleuthing and a manipulated image

  • There were also more serious claims that she was in a coma, or dead, or getting a divorce.
  • In the midst of this speculation, TMZ published a grainy photo of Catherine in the passenger seat of a car near Windsor Castle.
  • The public quickly realised the image was at best poorly photoshopped or at worst AI-generated.
  • The Associated Press, Getty Images, AFP and Reuters subsequently issued “kill notices” on the image, stating concerns it had been digitally manipulated.

Old media PR won’t work in a new media world

  • The situation with Catherine’s absence from public life exposes the limits of old media strategies in a “new media” world.
  • The Palace is used to being able to control media coverage through the royal rota, a select group of press outlets in the UK given access to royal events.
  • Yet the interest in Catherine’s health has prompted a number of statements to the press.
  • These old media strategies don’t seem to be working, with news outlets that are part of the royal rota reporting critically on the manipulated image.


The authors do not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Pineapple Express Hollywood Dispensary Celebrates its 2-Year Anniversary Amidst Growing Pains

Retrieved on: 
火曜日, 2月 20, 2024
LOS, Grammy Awards, OTC, TMZ, Pineapple Express, Pineapple, Hollywood and Vine, Partnership, Nightclub

LOS ANGELES, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pineapple Express Cannabis Company (OTC: PNXP) (the “Company” or “Pineapple Express”), a publicly traded company, today announced its 2-Year anniversary celebration of its flagship Pineapple Express Hollywood dispensary on the walk of fame in Hollywood, Ca., on the heels of resolving a partnership dispute.

Key Points: 
  • Dispensary’s 2nd anniversary celebration will be held at its flagship location at the iconic intersection of Hollywood & Vine, Saturday, February 24th from 12:00 to 4:00.
  • LOS ANGELES, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pineapple Express Cannabis Company (OTC: PNXP) (the “Company” or “Pineapple Express”), a publicly traded company, today announced its 2-Year anniversary celebration of its flagship Pineapple Express Hollywood dispensary on the walk of fame in Hollywood, Ca., on the heels of resolving a partnership dispute.
  • As reported by TMZ and other outlets, the investor star power at this location is impressive and includes a Grammy winning recording artist, an All-Pro retired football player, and well-known pop icons.
  • All have commemorative stars on the floor of the dispensary themed like the real walk of fame stars just steps away.

Mike Tyson recently launched a 6th to 12th grade Academy for students in Phoenix, Arizona

Retrieved on: 
木曜日, 2月 15, 2024
Multimedia, TTA, Education, TMZ, WWE, WWE Championship, Mixed martial arts, Student

PHOENIX, Feb. 15, 2024 /PRNewswire/ -- Tyson Transformational Technologies Academy's (Tyson's TTA) is a Cognia Accredited Micro-School in Arizona serving youth grades 6th to 12th grade. All tuition costs are covered through the Empowerment Scholarship Account (ESA Scholarship) and internal school scholarships. Tyson has generously given his name, likeness, time and talents to impact the lives of our future generations of youth in the Phoenix area with no compensation.

Key Points: 
  • PHOENIX, Feb. 15, 2024 /PRNewswire/ -- Tyson Transformational Technologies Academy's (Tyson's TTA) is a Cognia Accredited Micro-School in Arizona serving youth grades 6th to 12th grade.
  • Mike Tyson recently launched a 6th to 12th grade Academy for students in Phoenix, Arizona
    This marks a significant milestone in the world of education and philanthropy as Tyson's TTA is dedicated to emphasizing the importance and fostering the emotional, belief, and physiological intelligence.
  • It is a trailblazer in education that is committed to serving the diverse needs of middle and high school students.
  • The new educational institution, founded by Mike Tyson, aims to redefine learning by combining innovation, financial literacy, mentorship, and community engagement.

IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology

Retrieved on: 
水曜日, 2月 14, 2024
Glioblastoma, Neoplasm, PFS, Progression-free survival, Recurrence, Toxicity, Quality of life, TMZ, GBM, Cell, Safety, DDR, DRI, Patient, Brain, Survival, NKG2D, Temozolomide, DNA, Radiation, Vaccine

(NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.

Key Points: 
  • (NASDAQ: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced a publication in Frontiers in Immunology that reviews IN8bio’s novel approach for solid tumors, such as glioblastoma (GBM), an aggressive form of brain cancer.
  • Cellular therapies, particularly chimeric antigen receptor T cell therapies (CAR-T), have shown promise in hematologic malignancies but have faced significant challenges when applied to solid tumors like GBM.
  • The INB-200 and INB-400 studies by IN8bio addresses the challenges towards targeting solid tumors by harnessing the innate immune functions of gamma-delta T cells.
  • IN8bio is also conducting a Phase 2 clinical trial of a genetically modified autologous gamma-delta T cell therapy (INB-400) targeting newly diagnosed GBM.

Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma

Retrieved on: 
火曜日, 1月 9, 2024
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Quality of life, Temozolomide, Survival, Patient, GBM, Clinical trial, TMZ, Disease, Progression-free survival, Neoplasm, NANO, Glioblastoma, TRIDENT, Medical imaging

The TRIDENT study could unlock our ability to reach patients earlier in their treatment journey, further extending patient survival.

Key Points: 
  • The TRIDENT study could unlock our ability to reach patients earlier in their treatment journey, further extending patient survival.
  • The TRIDENT clinical trial is a randomized, open-label study designed to enroll 950 adult patients with newly diagnosed GBM.
  • Following maximal debulking surgery, patients enrolled in TRIDENT were randomized to receive either TTFields therapy, concomitant with TMZ and radiation therapy, or TMZ and radiation therapy for six weeks.
  • TRIDENT began enrolling patients in December 2020 and is the largest trial Novocure has conducted to date.

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Retrieved on: 
日曜日, 11月 19, 2023
Temozolomide, Safety, Glioblastoma, Dana–Farber Cancer Institute, GBM, Molecular medicine, Medicine, TMZ, Patient, Tokyo Stock Exchange, Immunohistochemistry, Neoplasm, Integrin alpha M, Harvard Medical School, Survival, CD74, Cleveland Clinic, Society, SNO, CD3, Standard Market Design, Life, Biopsy, Code, Pharmaceutical industry, Neurology

The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.

Key Points: 
  • The presentation also included data from preclinical studies which evaluated the combination of MN-166 (ibudilast) and anti-PD1 or anti-PD-L1 therapy in GBM models.
  • MN-166 (ibudilast) and TMZ combination treatment was safe and well-tolerated, and no unexpected adverse effects were reported.
  • We are eager to evaluate MN-166 (ibudilast) in combination with anti-PD1 and anti-PD-L1 therapies in a future clinical trial.
  • MediciNova is grateful to the patients and families for their invaluable participation in our trial.”